AI Article Synopsis

  • A systematic review and meta-analysis were conducted to evaluate the efficacy of botulinum toxin A (BTX-A) injections in children with neurogenic bladder (NB) who do not respond to traditional antimuscarinic treatments.
  • The review examined 19 studies, highlighting significant improvements, such as a 97.7 mL increase in cystometric capacity, a decrease in detrusor pressure by 25.2 cm HO, and a 73.4% incontinence resolution rate post-treatment.
  • However, the studies varied in quality and design, lacking a placebo comparison and control groups, indicating that the evidence for BTX-A's effectiveness is not firmly established.

Article Abstract

Purpose: We performed a systematic review and meta-analysis to assess the current evidence on the effectiveness of botulinum toxin A (BTX-A) intradetrusor injections in paediatric NB patients who are resistant to antimuscarinic treatments.

Methods: A study was carried out on PubMed, Medline, and Embase with the search terms: ('neurogenic bladder' OR 'myelomeningocele') AND 'toxin' AND ('children' OR 'paediatric'). The PICOS framework guided the search strategy and selection of studies in line with the PRISMA guidelines. Research involving original data that examined BTX-A in paediatric patients with NB was included. Studies were independently chosen and data were extracted by two reviewers.

Results: Nineteen studies (one randomized controlled trial, six prospective studies, and 12 retrospective studies) that investigated the clinical application of BTX-A injections in children with NB were identified. None of the studies compared BTX-A to a placebo, and most lacked a control group. Results showed that maximal cystometric capacity increased by an average of 97.7 mL (34.1-162% increase) (95% confidence interval [CI] 59.6 to 135.8), while maximal detrusor pressure decreased by 25.2 cm HO (95% CI -39.7 to -10.7). Bladder compliance improved by 5.3 mL/cm HO (95% CI 2.9 to 7.8). After treatment, the average incontinence resolution rate among patients was 73.4%. Urinary tract infections were reported by 77 patients (13.6%).

Conclusions: BTX-A administered intradetrusorally enhances cystometric capacity, compliance, and maximum neurogenic detrusor overactivity in paediatric patients suffering from neurogenic bladder. Nonetheless, this conclusion lacks support from studies with a high level of evidence.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ans.19309DOI Listing

Publication Analysis

Top Keywords

paediatric patients
12
botulinum toxin
8
neurogenic bladder
8
systematic review
8
review meta-analysis
8
cystometric capacity
8
studies
7
btx-a
5
patients
5
toxin treatment
4

Similar Publications

Excessive daytime sleepiness and its predictors among type 2 diabetes mellitus patients at central ethiopia.

Sci Rep

December 2024

Department of Pediatrics and Child Health Nursing, College of Medicine and Health Sciences, Injibara University, Injibara, Ethiopia.

Excessive daytime sleepiness is a common finding among type 2 diabetes mellitus patients. However there is scarce data that shows the magnitude of excessive daytime sleepiness, & its association with type 2 diabetes mellitus. Hence, the study aimed to assess the prevalence of excessive daytime sleepiness and its associated factors among type 2 diabetes mellitus patients at Wolkite University Specialized Hospital.

View Article and Find Full Text PDF

This study aimed to investigate the safety and effect of omitting chest tubes after thoracoscopic lobectomy in children with congenital lung malformation. A multicenter retrospective study was performed with 632 thoracoscopic lobectomy CLM patients in four hospitals between 2014.1 and 2023.

View Article and Find Full Text PDF

To investigate for the risk of uveitis among such patients. A retrospective cohort study utilized the TriNetX database and recruited pediatric autoimmune patients diagnosed between January 1st 2004 and December 31st 2022. The non-autoimmune cohort were randomly selected control patients matched by sex, age, and index year.

View Article and Find Full Text PDF

Pathogenic activating mutations in the fibroblast growth factor receptor 3 (FGFR3) drive disease maintenance and progression in urothelial cancer. 10-15% of muscle-invasive and metastatic urothelial cancer (MIBC/mUC) are FGFR3-mutant. Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.

View Article and Find Full Text PDF

E-cigarette/vaping-associated lung injury (EVALI) is strongly associated with vitamin E acetate and often occurs with concomitant tetrahydrocannabinol (THC) use. To uncover pathways associated with EVALI, we examined cytokines, transcriptomic signatures, and lipidomic profiles in bronchoalveolar lavage fluid (BALF) from THC-EVALI patients. At a single center, we prospectively enrolled mechanically ventilated patients with EVALI from THC-containing products (N = 4) and patients with non-vaping acute lung injury and airway controls (N = 5).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!